Latest News - Merck & Co. H

Friday, October 27, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Merck & Co. H

ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS

Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the proportion of patients with …

Read the full story

Tuesday, September 05, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Merck & Co. H

CLARITY Extension: Annual Short-Course Therapy with Investigational Oral Agent Effective in Relapsing MS

New results suggest that patients with relapsing multiple sclerosis (MS) treated with two annual short courses of the investigational cladribine tablets (EMD Serono) may have similar clinical benefits…

Read the full story